Charles River Laboratories International, Inc.

Based on a comprehensive analysis of CRL, the stock presents a conflicting picture with significant risks that currently outweigh its potential.

Technical & Valuation Outlook CRL is experiencing substantial downward pressure, having fallen over 25% in the past month and trading 30% below its 52-week high, underscoring its high volatility. While its financial health is stable with adequate liquidity and efficient cash conversion, its valuation appears stretched. The forward P/E of 34 and a very high PEG ratio of 7.1 suggest that expectations for a strong earnings recovery are already fully priced in, indicating overvaluation.

Risk Assessment The primary concern is its elevated risk profile. With a beta of 1.62, the stock is significantly more volatile than the market and has demonstrated a capacity for severe drawdowns. Combined with the lack of peer comparison data, it is difficult to contextualize its premium valuation or gauge its competitive standing, adding a layer of uncertainty for investors.

Investment Recommendation Given the combination of high volatility, a pronounced recent downtrend, and a valuation that appears to price in substantial future growth, CRL is not a compelling buy at this time. The stock's technical weakness and premium valuation create a high-risk entry point. Investors should monitor for signs of a sustained technical reversal and more attractive valuation levels before considering a position. For reference only; not investment advice.

RockFlow Model Forecast: Three Scenarios for 2026

Based on a comprehensive analysis, the 12-month outlook for CRL is cautious with a bearish bias. The primary catalyst for any positive reversal would be a significant earnings beat that justifies its premium valuation, coupled with a sustained technical recovery above key resistance levels.

Potential risks are pronounced and currently dominate the narrative. The stock's high beta of 1.62 exposes it to amplified losses in a weak market, while its stretched valuation (PEG ratio of 7.1) leaves little room for disappointment. The lack of a clear competitive benchmark adds to the uncertainty.

Given the lack of an analyst target price and the current negative momentum, a prudent target price range is difficult to establish. A more compelling entry point would likely be at a significantly lower valuation, suggesting the stock may test lower levels before stabilizing. Investors should wait for a confirmed reversal in both price and fundamentals.

Wall Street Consensus

Most Wall Street analysts are optimistic about Charles River Laboratories International, Inc.'s 12-month outlook, with consensus target around $161.35, indicating expected upside potential.

Overall, CRL has investment potential but also faces challenges. Here are key factors to weigh before investing.

CRL has delivered mixed returns characterized by significant recent weakness and high volatility, as reflected by its beta well above 1.0.

The stock has experienced severe short-term pressure, declining over 25% in the past month, which has more than erased its relatively modest 3-month loss, causing it to slightly underperform the market over that period. This sharp correction highlights its heightened volatility.

Currently trading approximately 30% below its 52-week high, the price is in the lower-middle portion of its annual range; while not at an extreme oversold level, the stock's significant drawdown and recent precipitous drop suggest it possesses elevated risk amid this downtrend.

Revenue & Profitability CRL's Q3 2025 revenue of $1.00 billion shows a slight sequential decrease from Q2's $1.03 billion. The company maintains stable profitability with a gross margin of 33.7% and net margin of 5.4%, though operating income margin improved to 13.3% from 9.7% in Q2 due to better cost control.

Financial Health The company demonstrates moderate leverage with a debt-to-equity ratio of 0.77 and total debt-to-capitalization of 43.6%. Interest coverage of 5.3x remains adequate, while the current ratio of 1.37 indicates sufficient short-term liquidity, though the cash ratio of 0.19 suggests limited immediate cash buffer.

Operational Efficiency CRL shows modest operational metrics with return on equity at 1.6% and asset turnover of 0.13. The 84-day cash conversion cycle indicates efficient working capital management, while free cash flow per share of $3.62 demonstrates solid cash generation relative to operations.

Valuation Level: CRL's negative trailing P/E ratio is not meaningful due to temporary earnings issues, but its forward P/E of approximately 34 suggests the market expects a significant earnings recovery. However, the extremely high PEG ratio of 7.1 indicates that this expected growth is already fully priced in, pointing toward overvaluation when considering growth prospects. The elevated EV/EBITDA of 49 further confirms that the stock trades at a premium based on cash flow metrics.

Peer Comparison: A peer comparison cannot be performed as industry average data is unavailable. This critical data point is necessary to contextualize CRL's valuation multiples against sector norms for P/E, P/B, and EV/EBITDA ratios. Without these benchmarks, it is impossible to determine whether CRL's multiples represent a sector premium or discount.

Volatility Risk: CRL exhibits significantly elevated volatility risk, as evidenced by its high Beta of 1.62, indicating it is expected to move 62% more than the broader market. This is corroborated by a substantial one-year maximum drawdown of -43.62%, highlighting the potential for severe capital depreciation during market downturns.

Other Risks: The absence of notable short interest mitigates risks associated with short squeezes and suggests a lack of significant bearish sentiment from sophisticated investors. However, this does not eliminate fundamental or sector-specific risks, and liquidity should still be assessed separately as it is not indicated here.